| 英文名稱 | Gracillin |
|---|---|
| 中文名稱 | 纖細薯蕷皂苷/纖細皂苷 |
| CAS號 | 19083-00-2 |
| 分子式 | C45H72O17 |
| 分子量 | 885.04 |
| 外觀 | |
| 熔點 | 290-293 °C |
| 酸度系數pKa | 12.78±0.70 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Gracillin |
|---|---|
| 中文名稱 | 纖細薯蕷皂苷/纖細皂苷 |
| CAS號 | 19083-00-2 |
| 分子式 | C45H72O17 |
| 分子量 | 885.04 |
| 外觀 | |
| 熔點 | 290-293 °C |
| 酸度系數pKa | 12.78±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000594
中文名稱：纖細薯蕷皂苷
中文別名：纖細皂苷
英文名稱：Gracillin
英文別名：Gracillin (6CI,7CI,8CI);(3β,25R)-Spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-β-D-glucopyranoside;25(R)-Diosgenin 3-O-β-D-glucopyranosyl-(1→3)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside;Diosgenin 3-O-(α-L-rhamnopyranosyl(1→2)-[β-D-glucopyranosyl(1→3)])-β-D-glucopyranoside;Diosgenin 3-O-β-gracillimatrioside;Dulcamarin C;Gracilline;Lilioglycoside G;NSC 698787;
分子式：C45H72O17
分子量：885.04
CAS號：19083-00-2
純度：HPLC≥98%
熔點：290-293 °C
密度：1.42±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數：12.78±0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規格：5mg10mg20mg50mg100mg500mg1g2g等應客戶需求包裝
供應單位：四川省維克奇生物科技有限公司
供應電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關注！ 新批次有現貨，歡迎咨詢。
| In-situ growth of a spherical vinyl-functionalized covalent organic framework as stationary phase for capillary electrochromatography-mass spectrometry analysis | ||
| 來源：SCI：TALANTA | 作者：Wenqi Sun | 備注：影響因子：6.057 |
| 引用描述 | ||
Evodiamine, rutaecarpine, limonin were purchased from Chengdu herbpurify CO., Ltd (Chengdu, China). Polyphyllin VII, polyphyllin E and gracillin were obtained from Sichuan Weikeqi Biological Technology Co., Ltd (Chengdu, China). Carbamazepine and oxcarbazepine were bought from TCI Chemical Industry Development Co., Ltd (Shanghai, China). | ||
| Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction | ||
| 來源：SCI：PHARMACOLOGICAL RESEARCH | 作者：Min Xu | 備注：影響因子：4.816 |
| 引用描述 | ||
hecogenin (1), diosgenin (2), ruscogenin (3), gitogenin (4), tigogenin (5), solasodine (6), (24S,25S)-3β, 24-di-hydroxy-5α-spirostan (7), dracaenol C (8), 25(27)-dehydroruscogenin (9), (1β, 3β, 14α, 15α, 20R, 22S, 25R)-spirost-5-ene-tetrol (10), peimine (11), peiminine (12), peimisine (13), isoverticine (14), trillin (15), polyphyllin VI (16), polyphyllin VII (17), pallidifloside D (18), prosapogenin A (19), spongipregnoloside A (20), dioscin(21), solasonine (22), solamargine (23), gracillin (24), polyphyllin I(25), timosaponin BII (26), timosaponinA-III(27), ophiopogonin D (28), protobioside (29), (22S,25S)-26-O-β-d-glucopyranosyl-22,25-epoxyfurost-5-en-3β,26-diol-3-O-α-l-rha-mnopyranosyl(1 → 2)-β-d-gluc (30), pallidifloside E (31), parispseudoside (32), methylprotodioscin (33), protodioscin (34), pseudoprotodioscin (35), YS-IX (36), pallidifloside A (37), pallidifloside H (38), digoxin (39), bisdigoxigenin (40), 7β, 14α, 21-tri-hydroxy-diosgenin (41), 12β,14α,21-tri-hydroxy-diosgenin (42), and 11β,14α-di-hydroxyldiosgenin (43) were purchase from Sichuan weikeqi biotechnology company (Sichuan province, China). Pooled human liver microsomes (HLMs, 20 mg/mL) and pooled human primary hepatocytes were purchased from Rild Research Institute for LiverDiseases (Shanghai, China). | ||
